Description

Stevanato Group: Riding The Biologics Boom—Can Its Injectable Solutions Become The Backbone Of Next-Gen Drug Delivery?

Stevanato Group’s financial performance for the fiscal year 2025 was characterized by both growth and challenges, highlighting key strategic areas as well as areas needing improvement. With a 9% increase in total company revenue at constant-currency rates, driven by the Biopharmaceutical and Diagnostic Solutions (BDS) segment, Stevanato showed strong traction in certain market areas. Notably, high-value solutions constituted 46% of total revenue, reflecting the company’s strategic focus on premium products, particularly the Nexa syringe, which saw significant demand increases. This strategic alignment led to a 160 basis point increase in gross profit margin, signifying effective execution against its strategic priorities. Despite these positives, challenges were evident within the Engineering Segment, which suffered a 23% revenue decline in the fourth quarter. This decrease resulted from slower order intake and a portfolio mix unfavorable to margins, despite operational improvements and optimization efforts.